Skip to main content

Day: May 7, 2024

Reliance, Inc. Announces Upcoming Conference Participation

SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) — Reliance, Inc. (NYSE: RS) announced today that its management team will participate in the following upcoming investor conferences:The BofA Securities 2024 Global Metals, Mining & Steel Conference on Tuesday, May 14, 2024 in Miami, Florida. Karla Lewis, President and Chief Executive Officer, and Arthur Ajemyan, Senior Vice President and Chief Financial Officer, are scheduled to present on Tuesday, May 14th at 5:30 p.m. ET and will participate in meetings with investors throughout the day. The Company’s presentation will be webcast live over the Internet, hosted on the Investors section of the Company’s website at investor.reliance.com. In addition to the live webcast, a replay will be available on the Company’s website for 90 days following the event. The KeyBanc 2024...

Continue reading

Descartes’ Annual Ecommerce Study Shows Online Buying Grows but 67% of Consumers Face Delivery Problems

ATLANTA and LONDON, May 07, 2024 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, released findings from Online Buying Grows, But Too Many Consumers Still Experiencing Delivery Woes, its third annual consumer sentiment study of ecommerce home delivery. The study shows that 39% of respondents made more online purchases in the period surveyed this year compared to last year, and that 57% made purchases in at least one new product category this year. While the study revealed that consumers in every demographic are increasing the volume and frequency of their online purchases, 67% of those surveyed encountered delivery problems. What’s more, delivery issues were also cited in the study as a potential barrier to future online buying. When consumers...

Continue reading

Costamare Inc. Sets the Date for Its First Quarter 2024 Results Release, Conference Call and Webcast

Earnings Release: Friday, May 10, 2024, Before Market OpensConference Call and Webcast: Friday, May 10, 2024, at 8:30 a.m. ET MONACO, May 07, 2024 (GLOBE NEWSWIRE) — Costamare Inc. (NYSE:CMRE), announced today that it will release its results for the first quarter ended March 31, 2024 before the market opens in New York on Friday, May 10, 2024. Conference Call Details: On Friday, May 10, 2024 at 8:30 a.m. ET, Costamare’s management team will hold a conference call to discuss the financial results. Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1-844-887-9405 (from the US), 0808-238-9064 (from the UK) or +1-412-317-9258 (from outside the US). Please quote “Costamare”. A replay of the conference call will be available until May 17, 2024. The United States replay...

Continue reading

VPG Reports Fiscal 2024 First Quarter Results

MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) — Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, today announced its results for its 2024 first fiscal quarter ended March 30, 2024. First Fiscal Quarter Highlights:Revenues of $80.8 million decreased 9.1% from a year ago. Gross profit margin was 43.4%, as compared to 41.9% reported a year ago. Operating margin was 8.6%, as compared to 11.2% reported a year ago. Adjusted operating margin* was 10.0%, as compared to 11.4% reported a year ago. Diluted net earnings per share of $0.44 compared to $0.51 reported a year ago. Adjusted diluted net earnings per share* of $0.42 compared to $0.52 reported a year ago. EBITDA* was $12.8 million with an EBITDA margin* of 15.8%. Adjusted EBITDA* was $12.3 million with an adjusted EBITDA margin*...

Continue reading

NNIT A/S: REVENUE GROWTH OF 12.2% AND 5.2% OPERATING MARGIN. FULL-YEAR FINANCIAL OUTLOOK IS MAINTAINED

Q1 2024 key highlightsThe first quarter results were as planned on an overall level. Organic revenue growth of 8.0% driven by Region Denmark and Region Europe partly offset by Region US and Region Asia. The performance of our downscaled Region Asia was impacted by continuing headwind and not as expected. Total revenue growth was 12.2% compared with last year. The group operating profit excluding special items increased from DKK 20m in Q1 2023 to DKK 23.9m in Q1 2024, equal to a group operating profit margin excl. special items of 5.2%. The internal projects leading to further optimization of the business such as implementing a new ERP system, relocation of offices in several locations and completion of the IT separation of the infrastructure business, are progressing according to plan. The full-year financial outlook for organic revenue...

Continue reading

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 trial in chronic neutropenia expected at a planned company investor event in June 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, May 07, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2024 and highlighted key recent and upcoming expected milestones. “With the recent U.S. approval of our first commercial product, XOLREMDI (mavorixafor) in WHIM syndrome, we are now deploying our experienced...

Continue reading

Highest Performances Holdings Inc. (NASDAQ: HPH) Increases Its Shareholding in Fanhua to 51.1%

GUANGZHOU, China, May 07, 2024 (GLOBE NEWSWIRE) — Highest Performances Holdings Inc. (NASDAQ: HPH) (“HPH” or the “Company”), today announced that it has increased its shareholding in Fanhua Inc. (“Fanhua”), a leading technology-driven independent financial service provider in China, from 50.1% to 51.1% as of May 6, 2024 by acquiring 565,000 American Depositary Shares of Fanhua on Nasdaq. Mr. Yinan Hu, Vice Chairman and CEO of HPH commented, “We are pleased to witness the solid progress that Fanhua has made in executing its various strategic initiatives, further bolstering our confidence in its growth potential. Considering that its current stock price does not fully reflect its long-term value, we will continue to increase our shareholdings in Fanhua and will continue to strongly support its development.” About Highest Performances...

Continue reading

Stallion Uranium Intersects Significant Conductive Structure

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: HM40) is proud to announce the successful completion of their inaugural winter 2024 diamond drilling program on its 100% owned Coffer Project situated in the prolific Southwestern Athabasca Basin in Saskatchewan, Canada. This milestone initiative was successful in encountering anomalous radioactivity in all three drill holes and culminated with the discovery of a large, deep-rooted conductive structure intersected on the final drill hole CF24-003 giving the target area the characteristics needed to host a large uranium deposit. HighlightsThree diamond drill holes totaling 2,798.2m were completed at the Appaloosa target area (Figure 4). Hole CF24-003 intersected...

Continue reading

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

LA JOLLA, Calif., May 07, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to expire no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibudilast). Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, “We are very pleased to receive the issue notification for this new patent and we believe it could increase the potential value of MN-166. New extended-release...

Continue reading

Calfrac Reports First Quarter 2024 Results

CALGARY, Alberta, May 07, 2024 (GLOBE NEWSWIRE) — Calfrac Well Services Ltd. (“Calfrac” or “the Company”) (TSX: CFW) announces its financial and operating results for the three months ended March 31, 2024. The following press release should be read in conjunction with the management’s discussion and analysis and interim consolidated financial statements and notes thereto as at March 31, 2024. Readers should also refer to the “Forward-looking statements” legal advisory and the section regarding “Non-GAAP Measures” at the end of this press release. All financial amounts and measures are expressed in Canadian dollars unless otherwise indicated. Additional information about Calfrac is available on the SEDAR+ website at www.sedarplus.ca, including the Company’s Annual Information Form for the year ended December 31, 2023. CEO’S MESSAGECalfrac’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.